**Appendix Table D129. Dose response in treatment discontinuation due to bothersome adverse effects with divalproex for migraine prevention in adults, results from low risk of bias randomized controlled clinical trial47**

| **Adverse Effect that Lead to Discontinuation** | **Daily Doses of Divalproex** | **Events/Randomized with Larger Dose** | **Events/Randomized with Smaller Dose** | **Relative Risk****(95% CI)** | **Absolute Risk Difference****(95% CI)** |
| --- | --- | --- | --- | --- | --- |
| Abdominal pain | 1000 mgvs. 500 mg | 1/43 | 0/45 | 3.1 (0.1 to 75.0) | 0.02 (-0.04 to 0.08) |
| Abdominal pain | 1500 mgvs. 1000 mg | 0/44 | 1/43 | 0.3 (0.0 to 7.8) | -0.02 (-0.09 to 0.04) |
| Alopecia | 1500 mgvs. 500 mg | 1/44 | 0/45 | 3.1 (0.1 to 73.3) | 0.02 (-0.04 to 0.08) |
| Alopecia | 1500 mgvs. 1000 mg | 1/44 | 0/43 | 2.9 (0.1 to 70.1) | 0.02 (-0.04 to 0.08) |
| Asthenia | 1000 mgvs. 500 mg | 0/43 | 1/45 | 0.3 (0.0 to 8.3) | -0.02 (-0.08 to 0.04) |
| Asthenia | 1500 mgvs. 500 mg | 0/44 | 1/45 | 0.3 (0.0 to 8.1) | -0.02 (-0.08 to 0.04) |
| Back pain | 1500 mgvs. 500 mg | 1/44 | 0/45 | 3.1 (0.1 to 73.3) | 0.02 (-0.04 to 0.08) |
| Back pain | 1500 mgvs. 1000 mg | 1/44 | 0/43 | 2.9 (0.1 to 70.1) | 0.02 (-0.04 to 0.08) |
| Constipation | 1000 mgvs. 500 mg | 0/43 | 1/45 | 0.3 (0.0 to 8.3) | -0.02 (-0.08 to 0.04) |
| Constipation | 1500 mgvs. 500 mg | 0/44 | 1/45 | 0.3 (0.0 to 8.1) | -0.02 (-0.08 to 0.04) |
| Depression | 1000 mgvs. 500 mg | 3/43 | 0/45 | 7.3 (0.4 to 137.6) | 0.07 (-0.02 to 0.16) |
| Depression | 1500 mgvs. 1000 mg | 0/44 | 3/43 | 0.1 (0.0 to 2.6) | -0.07 (-0.16 to 0.02) |
| Diarrhea | 1500 mgvs. 500 mg | 1/44 | 0/45 | 3.1 (0.1 to 73.3) | 0.02 (-0.04 to 0.08) |
| Diarrhea | 1500 mgvs. 1000 mg | 1/44 | 0/43 | 2.9 (0.1 to 70.1) | 0.02 (-0.04 to 0.08) |
| Emotional liability | 1500 mgvs. 500 mg | 1/44 | 0/45 | 3.1 (0.1 to 73.3) | 0.02 (-0.04 to 0.08) |
| Emotional liability | 1500 mgvs. 1000 mg | 1/44 | 0/43 | 2.9 (0.1 to 70.1) | 0.02 (-0.04 to 0.08) |
| Nausea | 1000 mgvs. 500 mg | 1/43 | 1/45 | 1.0 (0.1 to 16.2) | 0.00 (-0.06 to 0.06) |
| Nausea | 1500 mgvs. 500 mg | 4/44 | 1/45 | 4.1 (0.5 to 35.2) | 0.07 (-0.03 to 0.16) |
| Nausea | 1500 mgvs. 1000 mg | 4/44 | 1/43 | 3.9 (0.5 to 33.6) | 0.07 (-0.03 to 0.16) |
| Pharyngitis | 1000 mgvs. 500 mg | 1/43 | 0/45 | 3.1 (0.1 to 75.0) | 0.02 (-0.04 to 0.08) |
| Pharyngitis | 1500 mgvs. 1000 mg | 0/44 | 1/43 | 0.3 (0.0 to 7.8) | -0.02 (-0.09 to 0.04) |
| Pneumonia | 1000 mgvs. 500 mg | 0/43 | 1/45 | 0.3 (0.0 to 8.3) | -0.02 (-0.08 to 0.04) |
| Pneumonia | 1500 mgvs. 500 mg | 0/44 | 1/45 | 0.3 (0.0 to 8.1) | -0.02 (-0.08 to 0.04) |
| Somnolence | 1500 mgvs. 500 mg | 1/44 | 0/45 | 3.1 (0.1 to 73.3) | 0.02 (-0.04 to 0.08) |
| Somnolence | 1500 mgvs. 1000 mg | 1/44 | 0/43 | 2.9 (0.1 to 70.1) | 0.02 (-0.04 to 0.08) |
| Thinking abnormal | 1500 mgvs. 500 mg | 1/44 | 0/45 | 3.1 (0.1 to 73.3) | 0.02 (-0.04 to 0.08) |
| Thinking abnormal | 1500 mgvs. 1000 mg | 1/44 | 0/43 | 2.9 (0.1 to 70.1) | 0.02 (-0.04 to 0.08) |
| Vomiting | 1000 mgvs. 500 mg | 0/43 | 1/45 | 0.3 (0.0 to 8.3) | -0.02 (-0.08 to 0.04) |
| Vomiting | 1500 mgvs. 500 mg | 1/44 | 1/45 | 1.0 (0.1 to 15.8) | 0.00 (-0.06 to 0.06) |
| Vomiting | 1500 mgvs. 1000 mg | 1/44 | 0/43 | 2.9 (0.1 to 70.1) | 0.02 (-0.04 to 0.08) |
| Weight gain | 1500 mgvs. 500 mg | 1/44 | 0/45 | 3.1 (0.1 to 73.3) | 0.02 (-0.04 to 0.08) |
| Weight gain | 1500 mgvs. 1000 mg | 1/44 | 0/43 | 2.9 (0.1 to 70.1) | 0.02 (-0.04 to 0.08) |

CI = confidence interval

Bold = significant differences at 95% confidence limit when 95% CI of relative risk estimates do not include 1 and 95% CI of absolute risk difference estimates do not include 0